Literature DB >> 7646143

Humoral immune response to human aortic valve homografts.

J D Smith1, H Ogino, D Hunt, R M Laylor, M L Rose, M H Yacoub.   

Abstract

The humoral response to homograft valves in humans is largely unknown. The anti-human lymphocyte antigen (HLA) antibody production, specificity, and immunoglobulin class were examined sequentially in 73 patients undergoing aortic valve replacement. In addition, the long-term production of antibodies was examined in a cross-sectional study of 160 patients at periods varying from 1 to 15 years postoperatively. Human lymphocyte antigen antibodies were produced in 17 of 30 antibiotic-sterilized homografts (56%) and in 15 of 15 "homovital" homograft recipients, compared with 6 of the 28 control xenograft recipients (21%) (p < 0.001). The HLA antibodies were immunoglobulin G in all 15 homovital homografts, in 11 of 17 antibiotic-sterilized homografts, and in four of the six xenograft cases. Human lymphocyte antigen specificities could be assigned to the antibodies in 21 cases. In 10 of 11 cases in which donor HLA typing data were available, the antibodies detected were directed against donor HLA class I antigens. Of six possible determinants of HLA antibody production, the type of homograft valve implanted (homovital or antibiotic sterilized) correlated with antibody formation. In the cross-sectional study, 66 of the 85 homovital homograft recipients tested for HLA antibodies after 1 year were found to have antibodies, compared with 29 of 75 antibiotic-sterilized homograft recipients (p = 0.00003). We conclude that homografts appear to stimulate a strong donor HLA-specific antibody response, particularly of the immunoglobulin G class. This is most common in homovital valve recipients. These antibodies can persist for 15 years after operation. The clinical significance of this response requires further investigation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7646143     DOI: 10.1016/0003-4975(95)00275-p

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  5 in total

1.  Aortic valve replacement with a homovital valve.

Authors:  R Mehrotra; S Srivastava; B Airan; M A Koicha; N K Mehra; P Venugopal; A S Kumar
Journal:  Tex Heart Inst J       Date:  1997

2.  Decellularized Cryopreserved Allografts as Off-the-Shelf Allogeneic Alternative for Heart Valve Replacement: In Vitro Assessment Before Clinical Translation.

Authors:  Laura Iop; Adolfo Paolin; Paola Aguiari; Diletta Trojan; Elisa Cogliati; Gino Gerosa
Journal:  J Cardiovasc Transl Res       Date:  2017-03-09       Impact factor: 4.132

Review 3.  Immunologic considerations in heart transplantation for congenital heart disease.

Authors:  Beth D Kaufman; Robert E Shaddy
Journal:  Curr Cardiol Rev       Date:  2011-05

4.  Long-term Persistence of Allosensitization After Islet Allograft Failure.

Authors:  Paola Rios; David Baidal; Joana Lemos; Stephanie S Camhi; Marco Infante; Nathalia Padilla; Ana M Alvarez Gil; Virginia Fuenmayor; Jonathan Ambut; Fatima A Qasmi; Alejandro M Mantero; Shari Messinger Cayetano; Phillip Ruiz; Camillo Ricordi; Rodolfo Alejandro
Journal:  Transplantation       Date:  2021-11-01       Impact factor: 5.385

Review 5.  Revisiting the guidelines and choice the ideal substitute for aortic valve endocarditis.

Authors:  Francesco Nappi; Sanjeet Singh Avtaar Singh; Cristiano Spadaccio; Christophe Acar
Journal:  Ann Transl Med       Date:  2020-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.